Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25200436 | 0.86 | HTR2A (0.47) | HTR2AHTR2CHTR2BTAAR1ALDH1A1 | |
| SCHEMBL31095502 | 0.86 | HTR2A (0.47) | HTR2AHTR2CHTR2BTAAR1ALDH1A1 | |
| SCHEMBL31095263 | 0.82 | HTR2A (0.47) | HTR2AHTR2CHTR2BALDH1A1KEAP1 | |
| SCHEMBL25215053 | 0.82 | HTR2A (0.47) | HTR2AHTR2CHTR2BALDH1A1KEAP1 | |
| SCHEMBL4166591 | 0.79 | HTR2A (0.47) | HTR2AHTR2CHTR2BALDH1A1KEAP1 | |
| SCHEMBL29614959 | 0.78 | KEAP1 (0.53) | HTR2AHTR2CHTR2BKEAP1NFE2L2 | |
| SCHEMBL44782 | 0.78 | KEAP1 (0.53) | HTR2AHTR2CHTR2BKEAP1NFE2L2 | |
| SCHEMBL19031388 | 0.78 | HTR2A (0.57) | HTR2AHTR2CHTR2BTAAR1ALDH1A1 | |
| SCHEMBL25200431 | 0.77 | KEAP1 (0.52) | HTR2AHTR2CHTR2BALDH1A1PKM | |
| SCHEMBL31095257 | 0.77 | KEAP1 (0.52) | HTR2AHTR2CHTR2BALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289430-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150164904-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8815910-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164904-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A1 | HTR2A 1903/4885HTR2C 2556/4885HTR2B 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.